文献速递瓣膜外科

经导管与外科三尖瓣修复:Medicare受益人群分析

Transcatheter vs Surgical Tricuspid Valve Repair: An Analysis of Medicare Beneficiaries.
PubMed 文献 · Ann Thorac Surg · 2026-03-19

基于美国Medicare 2018-2022年数据,比较孤立性三尖瓣经导管缘对缘修复(T-TEER,n=1540)与孤立性外科三尖瓣修复(TVr,n=1221)患者的结局。外科TVr围术期死亡率更高,但风险调整后3年生存、心衰再入院及瓣膜再干预均优于T-TEER。

要点

  • 外科TVr未调整院内死亡率高于T-TEER(8.8% vs 2.1%),风险调整后仍更高(OR 2.83)。
  • 外科TVr风险调整后3年生存优于T-TEER(HR 0.76,P=.012)。
  • 外科TVr 3年心衰再入院(HR 0.79)与瓣膜再干预(HR 0.83)均低于T-TEER。

核心结论

  • 在症状性三尖瓣反流的Medicare患者中,外科TVr围术期风险更高,但风险调整后3年生存、心衰再入院和瓣膜再干预优于T-TEER。

研究设计与样本

  • 基于美国Medicare 2018-2022年数据的回顾性队列研究,排除心内膜炎与风湿性疾病。
  • 孤立性T-TEER 1540例,孤立性外科TVr 1221例;采用逆概率加权、多水平回归及竞争风险时间-事件分析进行双重稳健风险调整。

主要发现

  • 外科TVr未调整院内死亡率8.8% vs T-TEER 2.1%(P<.001)。
  • 未调整3年死亡率外科TVr 20.8% vs 26.2%(P=.025),瓣膜再干预0.9% vs 2.1%(P=.015)。
  • 风险调整后外科TVr院内死亡OR 2.83(P<.001),远期生存HR 0.76(P=.012)。
  • 风险调整后外科TVr总体再入院HR 0.87(P=.040)、心衰再入院HR 0.79(P=.001)、瓣膜再干预HR 0.83(P=.003)。

临床怎么用

  • 对严重症状性三尖瓣反流患者,心脏团队决策需权衡外科TVr较高围术期风险与其更优的3年生存、心衰再入院和瓣膜再干预结局。
  • 上述当代数据或可为未来临床试验设计和心脏团队决策提供参考。

局限性

  • 为回顾性行政数据库分析,结局依赖ICD-10编码定义合并症与衰弱,可能存在编码偏倚与残余混杂。
  • 研究对象限于美国Medicare受益人群,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with tricuspid regurgitation, surgical and transcatheter interventions aim to impact outcomes and symptomatic quality of life. We compared tricuspid transcatheter edge-to-edge repair (T-TEER) to isolated surgical tricuspid valve repair (TVr). METHODS: Assessing US Medicare data (2018-2022), excluding endocarditis and rheumatic disease, we evaluated all patients undergoing isolated T-TEER (n = 1540) or isolated TVr (n = 1221). International Classification of Diseases 10th revision codes were used to define comorbidities and frailty using validated metrics. Doubly robust risk adjustment was performed with inverse probability weighting, multilevel regression, and competing-risk time-to-event analyses. Outcomes of interest include procedural mortality, pacemaker, and kidney injury as well as 3-year freedom from death, valve reintervention, and heart failure readmission. RESULTS: Surgical TVr was associated with higher unadjusted hospital mortality (8.8% vs 2.1%, P < .001), but lower 3-year mortality (20.8% vs 26.2%, P = .025) and valve reintervention (0.9% vs 2.1%, P = .015). After risk adjustment, surgical TVr was associated with higher hospital mortality (odds ratio, 2.83, P < .001) but improved longitudinal survival compared with T-TEER (hazard ratio [HR], 0.76; P = .012). Surgical TVr was associated with lower rates of overall readmission (HR, 0.87; P = .040), heart failure-related readmission (HR, 0.79; P = .001), and valve reintervention (HR, 0.83; P = .003) at 3 years compared with T-TEER. CONCLUSIONS: Among Medicare patients with symptomatic tricuspid regurgitation, surgical TVr was associated with higher perioperative risk, but improved risk-adjusted 3-year survival, heart failure readmission, and valve reintervention compared with T-TEER. These contemporary data may inform future trial designs and heart team decision-making for patients with severe symptomatic tricuspid regurgitation.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Mehaffey JH, Daggubati R, Jagadeesan V, et al. Transcatheter vs Surgical Tricuspid Valve Repair: An Analysis of Medicare Beneficiaries. Ann Thorac Surg. 2026. PMID: 41864530. doi:10.1016/j.athoracsur.2026.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。